| Basics |
Verastem, Inc.
Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib.
|
| IPO Date: |
February 1, 2012 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$662.84M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.17 | 3.40%
|
| Avg Daily Range (30 D): |
$0.32 | 4.41%
|
| Avg Daily Range (90 D): |
$0.27 | 3.97%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.19M |
| Avg Daily Volume (30 D): |
2.82M |
| Avg Daily Volume (90 D): |
2.34M |
| Trade Size |
| Avg Trade Size (Sh.): |
260 |
| Avg Trade Size (Sh.) (30 D): |
132 |
| Avg Trade Size (Sh.) (90 D): |
128 |
| Institutional Trades |
| Total Inst.Trades: |
575 |
| Avg Inst. Trade: |
$1.81M |
| Avg Inst. Trade (30 D): |
$1.26M |
| Avg Inst. Trade (90 D): |
$1.39M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.03M |
| Avg Closing Trade (30 D): |
$1.22M |
| Avg Closing Trade (90 D): |
$1.29M |
| Avg Closing Volume: |
118.75K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-3.45
|
$-.39
|
$-.96
|
|
Diluted EPS
|
$-3.56
|
$-.62
|
$-.96
|
|
Revenue
|
$ 2.14M
|
$ 2.14M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -166.56M
|
$ -25.93M
|
$ -52.1M
|
|
Operating Income / Loss
|
$ -156.56M
|
$ -43.76M
|
$ -44.17M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 5.45M
|
$ M
|
$ M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jun 01, 2023:
1:12
|
|
|
|
